The project company Belina is running an innovative project in early phase and is developing a product for treatment of breast cancer.After changing its strategy and organization in 2018, Aqilion decided to transfer its holdings in Belina AB to its founder and innovator since Aqilion is no longer an ideal partner for the continued development of Belina as a company and commercialization of its future product.
Many years of research at Lund University, in Sweden, have shown that long-term treatment with a specific pharmaceutical substance combined with current treatment regimens for breast cancer can lead to significantly improved survival. The innovation is based on research in oncology under the leadership of Professor Håkan Olsson at Lund University. After investigating data and registry studies, the research group found higher survival among patients treated with an approved medication in parallel with their breast cancer treatment. Belina was founded as an extremely early innovation project within what was known as the PULS group at the time, currently known as Aqilion.
“The innovation is based on large registry studies and solid research in breast cancer and is extremely interesting. Based on Aqilion’s new strategy, we have determined that we are no longer the right partner for commercial development of the project and the Board of Directors has therefore decided to transfer Aqilion’s stake in Belina to its founder. We hope that by doing so, Håkan Olsson’s research group will be able to continue to take advantage of new data and pave the way so their discovery will benefit patients in the future,” says Sarah Fredriksson, CEO of Aqilion.
About AQILION AB
Aqilion is a Swedish life science company that identifies unique pharmaceutical projects at an early phase in the drug discovery process and develops them in preparation for clinical trials. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to market. The business model is based on involvement at an early stage and close collaboration with the innovator, regardless of whether the project is initiated by an external researcher, internal development project, or industrial partner. Aqilion prefers projects aimed at niche markets. Specialty medications (high-cost, high complexity and/or high touch drugs) and orphan drugs (drugs to treat diseases so rare that they would be unprofitable to produce without government assistance) are particularly interesting. Aqilion has its headquarters in Helsingborg, Sweden. Please visit www.www.aqilion.com